1h Free Analyst Time
The neurological biomarkers market is forecasted to grow by USD 7.82 bn during 2023-2028, accelerating at a CAGR of 13.01% during the forecast period. The report on the neurological biomarkers market provides a holistic analysis, market size and forecast, trends, growth drivers, and challenges, as well as vendor analysis covering around 25 vendors.Speak directly to the analyst to clarify any post sales queries you may have.
The report offers an up-to-date analysis regarding the current market scenario, the latest trends and drivers, and the overall market environment. The market is driven by rising incidence of neurological disorders, growth in clinical trials for neurological disease-specific biomarkers, and increasing initiatives and support from governments to improve neurological healthcare access.
The neurological biomarkers market is segmented as below:
By End-user
- Hospitals
- Clinical diagnostic centers
- Research organizations and others
By Indication
- AD
- PD
- ASD
- MS
- Others
By Geographical Landscape
- North America
- Europe
- Asia
- Rest of World (ROW)
The report on the neurological biomarkers market covers the following areas:
- Neurological biomarkers market sizing
- Neurological biomarkers market forecast
- Neurological biomarkers market industry analysis
The study was conducted using an objective combination of primary and secondary information including inputs from key participants in the industry. The report contains a comprehensive market and vendor landscape in addition to an analysis of the key vendors.
The publisher presents a detailed picture of the market by the way of study, synthesis, and summation of data from multiple sources by an analysis of key parameters such as profit, pricing, competition, and promotions. It presents various market facets by identifying the key industry influencers. The data presented is comprehensive, reliable, and a result of extensive research - both primary and secondary. The market research reports provide a complete competitive landscape and an in-depth vendor selection methodology and analysis using qualitative and quantitative research to forecast the accurate market growth.
Table of Contents
1 Executive Summary
2 Market Landscape
3 Market Sizing
4 Historic Market Size
5 Five Forces Analysis
6 Market Segmentation by End-user
7 Market Segmentation by Indication
8 Customer Landscape
9 Geographic Landscape
10 Drivers, Challenges, and Trends
11 Vendor Landscape
12 Vendor Analysis
13 Appendix
List of Exhibits
Executive Summary
The publisher recognizes the following companies as the key players in the global neurological biomarkers market: Abbott Laboratories, ACROBIOSYSTEMS INC., Advanced Brain Monitoring Inc., Alseres Pharmaceuticals Inc, Bio Rad Laboratories Inc., bioMerieux SA, Charles River Laboratories International Inc., EATRIS ERIC, Eli Lilly and Co., Enzo Biochem Inc., F. Hoffmann La Roche Ltd., Fujirebio Holdings Inc., IQVIA Holdings Inc., Merck KGaA, Metabolon Inc., PerkinElmer Inc, Proteome Sciences plc, QIAGEN NV, Quanterix Corp., and Thermo Fisher Scientific Inc..Commenting on the report, an analyst from the research team said: 'The latest trend gaining momentum in the market is increasing focus on accurate neurological diagnostics.'
According to the report, one of the major drivers for this market is the rising incidence of neurological disorders.
The study was conducted using an objective combination of primary and secondary information including inputs from key participants in the industry. The report contains a comprehensive market and vendor landscape in addition to a SWOT analysis of the key vendors.
Companies Mentioned (Partial List)
A selection of companies mentioned in this report includes, but is not limited to:
- Abbott Laboratories
- ACROBIOSYSTEMS INC.
- Advanced Brain Monitoring Inc.
- Alseres Pharmaceuticals Inc
- Bio Rad Laboratories Inc.
- bioMerieux SA
- Charles River Laboratories International Inc.
- EATRIS ERIC
- Eli Lilly and Co.
- Enzo Biochem Inc.
- F. Hoffmann La Roche Ltd.
- Fujirebio Holdings Inc.
- IQVIA Holdings Inc.
- Merck KGaA
- Metabolon Inc.
- PerkinElmer Inc
- Proteome Sciences plc
- QIAGEN NV
- Quanterix Corp.
- Thermo Fisher Scientific Inc.